Article ; Online: Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
2018 Volume 331, Page(s) 22–29
Abstract: Hemophilia A is a X-linked recessive bleeding disorder consecutive to the lack of circulating pro-coagulant factor VIII (FVIII). The most efficient strategy to treat or prevent bleeding in patients with hemophilia A relies on replacement therapy using ... ...
| Abstract | Hemophilia A is a X-linked recessive bleeding disorder consecutive to the lack of circulating pro-coagulant factor VIII (FVIII). The most efficient strategy to treat or prevent bleeding in patients with hemophilia A relies on replacement therapy using exogenous FVIII. Commercially available recombinant FVIII are produced using an expensive perfusion technology in stainless steel fermenters. A fed-batch fermentation technology was recently developed to produce 'Neureight', a full-length recombinant human FVIII, in Chinese hamster ovary (CHO) cells. Here, we investigated the structural and functional integrity and lack of increased immunogenicity of Neureight, as compared to two commercially available full-length FVIII products, Helixate and Advate, produced in baby hamster kidney or CHO cells, respectively. Our results demonstrate the purity, stability and functional integrity of Neureight with a standard specific activity of 4235 ± 556 IU/mg. The glycosylation and sulfation profiles of Neureight were similar to that of Advate, with the absence of the antigenic carbohydrate epitopes α-Gal and Neu5Gc, and with sulfation of Y1680, that is critical for FVIII binding to von Willebrand factor (VWF). The endocytosis of Neureight by human immature dendritic cells was inhibited by VWF, and its half-life in FVIII-deficient mice was similar to that of Advate, confirming unaltered binding to VWF. In vitro and in vivo assays indicated a similar immunogenicity for Neureight, Advate and Helixate. In conclusion, the production of full-length FVIII in a fed-batch fermentation mode generates a product that presents similar biochemical, functional and immunogenic properties as products developed using the classical perfusion technology. |
|---|---|
| MeSH term(s) | Animals ; Bioreactors ; CHO Cells ; Cricetinae ; Cricetulus ; Dendritic Cells/immunology ; Dendritic Cells/metabolism ; Endocytosis/immunology ; Factor VIII/genetics ; Factor VIII/immunology ; Factor VIII/metabolism ; Fermentation ; Hemophilia A/drug therapy ; Hemophilia A/immunology ; Humans ; Male ; Mice, Inbred C57BL ; Mice, Knockout ; Recombinant Proteins/immunology ; Recombinant Proteins/metabolism ; Recombinant Proteins/therapeutic use |
| Chemical Substances | Recombinant Proteins ; F8 protein, human (839MOZ74GK) ; Factor VIII (9001-27-8) |
| Language | English |
| Publishing date | 2018-05-05 |
| Publishing country | Netherlands |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 80094-6 |
| ISSN | 1090-2163 ; 0008-8749 |
| ISSN (online) | 1090-2163 |
| ISSN | 0008-8749 |
| DOI | 10.1016/j.cellimm.2018.05.002 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 417: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.